Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2012 Financial Results
Progenics Pharmaceuticals, Inc. (PGNX) today announced its results of operations for the fourth quarter and year end 2012.
Net loss for the fourth quarter was $0.3 million or $0.01 diluted per share, compared to net loss of $10.7 million or $0.32 diluted per share in the 2011 period. Net loss for the year was $35.4 million or $1.02 diluted per share, compared to net income of $10.4 million or $0.31 diluted per share in 2011. The 2012 results include revenue from partnering two proprietary research programs, while 2011 results reflect upfront payment and reimbursement revenue from the company's Relistor(R) collaboration with Salix Pharmaceuticals.
- Published: 15 March 2013
- Written by Editor